13. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial
susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax
in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-96. Epub 2011/12/21. doi:
10.1200/JCO.2011.34.7898. PubMed PMID: 22184378.
14. Cidado JS, J.P. Gibbons, F.D. Hennessy, E.J. Ioannidis, S. and Clark, E.A. AZD4320 is a potent,
dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models.
Proceedings: AACR Annual Meeting 2018. 2018;78(13).
15. Phillips A. ABBV-1551: A First-In-Class Bcl-xL Inhibitor Antibody Drug Conjugate. In:
Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2019 March
31-April 3; Atlanta (GA) Philadelphia (PA): AACR; 2019 Oral Abstract.
